IPR Pharmaceuticals, Inc. – FDA 483, Jun 14, 2018
An FDA inspection of IPR Pharmaceuticals, Inc. in Canovanas, PR, revealed a significant deficiency in control procedures for manufacturing processes. The firm failed to establish adequate controls for processes that could cause variability in in-process material and drug product characteristics. This was evidenced by temperature and humidity excursions affecting Crestor 10mg core tablets, leading to out-of-trend results for assay and degradation products, without sufficient stability data or monitoring to support product release.
ID · 6167fbc9-2e2d-4eb3-9d94-b1d46f975693
Comes with the profile
KRA (KeyPedia Risk Analysis)
How likely the FDA is to take enforcement action in the next 12 months.
Example18-month trend
Form 483 · June 14, 2018
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every IPR Pharmaceuticals, Inc. document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA